Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has received approval from the National Medical Products Administration for its product, Perfluorohexyl Octanoate Eye Drops, aimed at treating Meibomian Gland Dysfunction (MGD) related dry eye [1][2]. Group 1: Product Information - Product Name: Perfluorohexyl Octanoate Eye Drops (SHR8058) [1] - Dosage Form: Ophthalmic preparation [1] - Specification: 3ml [1] - Registration Category: Reference to Class 3 generic drug [1] - Prescription Status: Prescription drug [1] - Approved Indication: Treatment of dry eye related to Meibomian Gland Dysfunction [1]. Group 2: Market Context - The prevalence of dry eye in China is reported to be between 21% and 30% [1]. - Clinical studies indicate that 69% to 86% of dry eye patients suffer from MGD, highlighting the need for targeted treatments [1]. - Current treatments for MGD lack a specific drug, emphasizing the demand for effective and safe therapeutic options [1]. Group 3: Product Development and Investment - The eye drops consist of 100% Perfluorohexyl Octanoate, which stabilizes the tear film and prevents excessive evaporation [2]. - The product can penetrate the Meibomian glands to dissolve viscous secretions, addressing MGD-related dry eye [2]. - The total research and development investment for the product has reached approximately 107.53 million yuan [2].

Group 1 - The report highlights that innovative drugs are leading the pharmaceutical sector's market trends, with valuations expected to continue recovering [3][7][10] - The trend of innovative drugs going overseas is accelerating, which is likely to sustain the main market momentum [3][28] - The report indicates that the overall performance of the pharmaceutical sector faced pressure in Q1 2025, with a year-on-year revenue decline of 4.34% and a net profit drop of 8.87% [4][5] Group 2 - The report notes that the commercialization of domestic biotech innovative drug companies is entering a stable phase, with a significant revenue increase of 36% year-on-year in 2024, reaching 92.43 billion yuan [29][57] - It is projected that the domestic market for innovative drugs could reach 446 billion yuan by 2030, assuming a compound annual growth rate of 30% over the next six years [57][61] - The report emphasizes that the existing overseas licensing deals could yield a sales share of approximately 14.5 billion USD, based on conservative estimates of project success [61][62] Group 3 - The report suggests that there are opportunities for gradual recovery in various sub-sectors, including CXO, traditional Chinese medicine, and retail pharmacies, as operational improvements are expected [3][28] - The report identifies a significant increase in the holdings of innovative drug stocks by public funds, with a notable rise in the proportion of biotech innovative drug holdings [14][24] - The report outlines that the innovative drug sector is expected to benefit from breakthroughs in medical technology, including surgical robots and AI in healthcare [3][4][28]

Group 1: IPO Market Overview - In 25H1, A-shares issued 48 new stocks, raising a total of 38 billion yuan, with a month-on-month decrease of 5 stocks but a year-on-year increase of 5 stocks[3] - The number of newly accepted IPO projects reached 150, with 123 accepted in June alone, indicating a recovery in the IPO market[3] - As of June 30, 2025, there are 298 IPO projects pending approval, with a total proposed fundraising of 281.4 billion yuan[3] Group 2: Market Performance and Trends - The average first-day increase for new stocks in 25H1 was 215.7%, although this represents a decrease of 143 percentage points from the previous period[3] - The average price-to-earnings (PE) ratio for new stocks in 25H1 was 20 times, with a discount of 41% compared to comparable companies, marking a historical high for the discount rate[3] - The proportion of new stocks that exceeded their fundraising targets increased, with over 40% of new stocks experiencing oversubscription in June[3] Group 3: Participation and Allocation - The number of participants in offline inquiries increased significantly, with the average number of participants in the main board, ChiNext, and Sci-Tech Innovation Board rising by 8%, 14%, and 11% respectively[3] - The allocation ratio for preferred participants decreased significantly, with main board, ChiNext, and Sci-Tech Innovation Board allocation ratios at 0.0133%, 0.0272%, and 0.0401% respectively, reflecting a month-on-month decline of 18%, 19%, and 17%[3] - The expected return for 2 billion yuan scale preferred/non-preferred participants in 25H2 is projected to be 2.77% and 2.03% respectively[3] Group 4: Risks and Future Outlook - Risks include potential changes in the IPO review pace, adjustments in issuance regulations, fluctuations in investor participation, and the quality/quantity of application projects[3] - The expectation for 25H2 is a stable increase in the volume of new stocks, with a projected first-day increase of 140%-180%, which is lower than the average level in the first half of the year[3]

Investment Rating - The report maintains an "Outperform" rating for A-Shares including Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, WuXi AppTec, Asymchem Laboratories, Hangzhou Tigermed Consulting, and APT Medical [6][32] - The report also maintains an "Outperform" rating for H-Shares including PATEO, Hansoh Pharmaceutical Group, Innovent Biologics, WuXi XDC Cayman, Luye Pharma Group, and BeiGene [6][32] Core Insights - The commercial insurance innovative drug list is expected to be released soon, which is anticipated to improve the domestic market significantly [33] - The National Healthcare Security Administration and National Health Commission have released measures to support the high-quality development of innovative drugs, focusing on high-innovation drugs with significant clinical value [33] - The pharmaceutical sector underperformed the market in June 2025, with the Shanghai Composite Index rising by 2.9% while the SW Pharma Bio index rose by only 0.7% [34] - The Hang Seng Healthcare sector outperformed the market with an increase of 8.4% in June 2025, while the U.S. S&P Healthcare Select Sector underperformed with a rise of only 1.9% [35] Summary by Sections - **Investment Highlights**: Continuous positive outlook for innovative drugs and industry chain, with specific A-Shares and H-Shares recommended for investment [32][6] - **Market Performance**: In June 2025, the pharmaceutical sector's performance was weak compared to the overall market, ranking 19th among Shenwan primary industries [34] - **Sub-sector Analysis**: The best-performing sub-sectors included medical services (+4.8%), chemical preparations (+0.8%), and chemical raw materials (+0.5%) [34][20] - **Stock Performance**: Top gainers in the pharmaceutical sector included Zhejiang Anglikang Pharmaceutical (+146.4%) and Hubei Huaqiang High-Tech Co., Ltd. (+67.4%), while top losers included Kexing Biopharm Co., Ltd. (-28.7%) [34][23]

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-099 江苏恒瑞医药股份有限公司 关于获得药品注册批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司成都盛迪医 药有限公司收到国家药品监督管理局（以下简称"国家药监局"）的通知，批准 公司产品全氟己基辛烷滴眼液上市，用于治疗睑板腺功能障碍（MGD）相关干眼。 现将相关情况公告如下： 一、药品的基本情况 药品名称：全氟己基辛烷滴眼液（SHR8058） 剂型：眼用制剂 规格：3ml 注册分类：参照 3 类仿制药 受理号：CXHS2300021 批准的适应症：本品用于治疗睑板腺功能障碍相关干眼。 二、药品的其他情况 《中国干眼临床诊疗指南（2023 年）》[1]提到，我国干眼的发病率为 21%-30%。 一项临床研究结果显示[2,3]，69%-86%的干眼人群患有 MGD。这表明在治疗干眼病 时，针对睑板腺功能障碍的治疗显得尤为重要。根据《中国睑板腺功能障碍专家 共识：诊断和治疗（2023 年）》[4 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-098 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司苏州盛迪亚 生物医药有限公司收到国家药品监督管理局（以下简称"国家药监局"）核准签 发关于 SHR-4506 注射液的《药物临床试验批准通知书》，将于近期开展临床试 验。现将相关情况公告如下： 一、药物的基本情况 SHR-4506 注射液是公司自主研发的 1 类治疗用生物制品，在临床前动物模 型中展现出良好的抗肿瘤活性，拟用于治疗晚期恶性肿瘤。经查询，目前国内外 尚无同类药物获批上市。截至目前，SHR-4506 注射液相关项目累计研发投入约 1,992 万元。 三、风险提示 根据我国药品注册相关的法律法规要求，药物在获得药物临床试验批准通知 书后，尚需开展临床试验并经国家药监局审评、审批通过后方可生产上市。药品 从研制、临床试验报批到投产的周期长、环节多，药品研发及至上市容易受到一 些不 ...

上 半 年 ， A 股 IPO 募 集 总 额 达 373.55 亿 元 ， 同 比 增 长 14.96%； 港 股 IPO 融 资 规 模 达 974.25 亿 元 ， 同 比 激 增 688.56%。 作者： 牛钰 封图：图虫创意 从年初的"松动"信号到年中节点，IPO（首次公开发行）市场节奏和主线的变化一直牵动着资本市 场的神经。回头来看，在政策优化和市场复苏的双向加持下，2025年IPO市场的活跃度骤起，融资 项目与规模显著回暖。 Wind数据显示，截至6月30日，上半年A股共有51只新股上市，同比增加7家，IPO募集总额达 373.55亿元，同比增长14.96%。其中，9只新股募资金额超过10亿元，中策橡胶（603049.SH）首 发募资金额最高，达40.66亿元。 港股IPO市场更是火热"出圈"，上半年共有43家企业成功上市，IPO融资规模达1067.13亿港元（约 合人民币974.25亿元），同比激增688.56%。按交易所排名，港交所的IPO融资规模位居全球榜 首，居于其后的纳斯达克交易所在上半年有79宗IPO（剔除特殊目的收购公司），筹资约90.74亿 美元（约合人民币650.32亿元）。 ...

经济观察报记者 邹永勤 近日，创新药领域政策不断。 为进一步完善全链条支持创新药发展举措，推动创新药高质量发展，2025年6月30日，国家医保局、国家卫生健康委联合对外印发《支持创新药高质量发展 的若干措施》（下称《若干措施》）。 紧接着7月1日，国家医保局根据《若干措施》的要求，研究起草了《2025年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录 调整工作方案（征求意见稿）》等文件，并向社会公开征求意见。 对此，浙江盛元私募基金管理有限公司合伙人郭永智向记者表示，近年来一系列相关扶持政策的出炉，很好地构建了支持创新药高质量发展的闭环体系，从 而有力促进了我国从 "创新药大国" 向"创新药强国"的转型。 创新药扶持政策连续加码 "此次《若干措施》的出炉，是对过往一系列创新药扶持政策在连贯性方面的进一步强化。"郭永智在接受记者采访时说。 郭永智是暨南大学药理学博士，目前在基金公司主要负责生物医疗大健康的投资，对创新药领域有着长期的跟踪研究。据他介绍，自2019年百济神州的泽布 替尼在美国成功获批实现零的突破后，中国创新药企业的出海授权金额不断激增、全球化进程明显加快，加上AI制药技术不断 ...

富时中国A50指数连续 金十图示：2025年07月03日（周四）富时中国A50指数成分股今日收盘行情一览：证券、消费电子、家电等板块收高，石油、煤 炭等板块收低，银行、保险等板块涨跌不一 -0.01(-0.18%) +0.06(+0.71%) +0.03(+0.71%) 保险 中国太保 中国平安 12,000 中国人保 电机 3825.38亿市值 3573.96亿市值 10161.31亿市值 5.06亿成交额 18.17亿成交额 6.14亿成交额 55.80 37.15 8.65 +0.03(+0.08%) -0.01(-0.02%) -0.04(-0.46%) 酸酒行业 贵州茅台 五粮液 山内对酒 17782.74亿市值 2142.50亿市值 4643.18亿市值 34.57亿成交额 10.02亿成交额 14.64亿成交额 1415.60 175.62 119.62 +6.00(+0.43%) 0.00(0.00%) +0.44(+0.37%) 术学体 北方华创 寒武纪-U 海光信息 HYGON 2368.09亿市值 2289.63亿市值 3146.22亿市值 13.25亿成交额 21.74亿成交额 12. ...

Core Viewpoint - The steel industry is experiencing a significant price increase due to production cuts driven by environmental regulations and government policies aimed at eliminating outdated capacity. This has led to a reduction in steel output expectations, particularly in Tangshan, where a 30% production cut has been mandated from July 4 to July 15. The market anticipates further impacts on steel production as a result of these measures [1][3]. Group 1: Steel Industry Insights - The recent meeting of the Financial and Economic Committee emphasized the need to push for the elimination of outdated production capacity, directly influencing the steel market [1]. - Tangshan steel mills have received directives for a 30% production cut, which is expected to significantly lower steel inventories and production levels [1]. - The China Iron and Steel Association reported that steel billet exports in the first four months of 2025 have already surpassed the total for 2024, prompting suggestions for export restrictions [1]. - A total of approximately 30 million tons of production cuts have been ordered for the year, coinciding with a seasonal demand lull, which has heightened market expectations for reduced steel output [1]. Group 2: Market Reactions and Trends - Longjiang Securities noted that administrative production cuts could act as a bullish option for the steel sector, particularly in July, which is traditionally a slow season for demand [3]. - The announcement of production cuts in the photovoltaic glass sector has also led to significant price increases in that market, indicating a broader trend of supply-side reforms impacting various sectors [3]. - The steel sector saw a strong rally in stock prices, with companies like Liugang and Chongqing Steel hitting their daily price limits amid these developments [9][10]. Group 3: Broader Economic Context - The overall A-share market experienced a decline, with major indices falling and a significant number of stocks trading lower, reflecting broader economic pressures [9]. - The government is expected to focus on structural adjustments across multiple industries, including steel, refining, and new energy sectors, as part of its economic strategy [7]. Group 4: Investment Trends - Institutional investors have begun to sell off some positions in response to the recent price increases in steel, indicating a cautious approach to the current market dynamics [1][4]. - The market's reaction to production cuts in both the steel and photovoltaic sectors suggests a growing trend towards supply-side management as a means to stabilize prices and manage excess capacity [3].